PL3180356T3 - Ludzkie przeciwciało anty-fgfr4 - Google Patents
Ludzkie przeciwciało anty-fgfr4Info
- Publication number
- PL3180356T3 PL3180356T3 PL15748050T PL15748050T PL3180356T3 PL 3180356 T3 PL3180356 T3 PL 3180356T3 PL 15748050 T PL15748050 T PL 15748050T PL 15748050 T PL15748050 T PL 15748050T PL 3180356 T3 PL3180356 T3 PL 3180356T3
- Authority
- PL
- Poland
- Prior art keywords
- human anti
- fgfr4 antibody
- fgfr4
- antibody
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14180555 | 2014-08-11 | ||
| PCT/EP2015/068440 WO2016023894A1 (en) | 2014-08-11 | 2015-08-11 | Human anti-fgfr4 antibody |
| EP15748050.0A EP3180356B1 (en) | 2014-08-11 | 2015-08-11 | Human anti-fgfr4 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3180356T3 true PL3180356T3 (pl) | 2020-04-30 |
Family
ID=51300622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15748050T PL3180356T3 (pl) | 2014-08-11 | 2015-08-11 | Ludzkie przeciwciało anty-fgfr4 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10358498B2 (pl) |
| EP (1) | EP3180356B1 (pl) |
| JP (2) | JP7011939B2 (pl) |
| ES (1) | ES2764418T3 (pl) |
| PL (1) | PL3180356T3 (pl) |
| TW (1) | TWI710575B (pl) |
| WO (1) | WO2016023894A1 (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2223935A3 (en) | 1998-12-08 | 2010-11-24 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
| EP3095465A1 (en) * | 2015-05-19 | 2016-11-23 | U3 Pharma GmbH | Combination of fgfr4-inhibitor and bile acid sequestrant |
| US10995143B2 (en) | 2016-02-10 | 2021-05-04 | Daiichi Sankyo Europe Gmbh | Combination of human anti-FGFR4 antibody and Sorafenib |
| WO2018055503A1 (en) | 2016-09-20 | 2018-03-29 | Novartis Ag | Combination comprising a pd-1 antagonist and an fgfr4 inhibitor |
| MA46712A (fr) | 2016-11-02 | 2019-09-11 | Novartis Ag | Combinaisons d'inhibiteurs de fgfr4 et de chélateurs de l'acide biliaire |
| EP3444275A1 (en) * | 2017-08-16 | 2019-02-20 | Exiris S.r.l. | Monoclonal antibody anti-fgfr4 |
| CN111670247B (zh) * | 2017-12-08 | 2024-01-05 | 京诊断株式会社 | 制备癌球状体的方法和选择结直肠癌患者的方法 |
| CN111471109B (zh) * | 2020-04-08 | 2021-07-23 | 中国科学院深圳先进技术研究院 | 一种抗成纤维细胞生长因子受体4单克隆抗体及其制备方法和用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2933702A1 (fr) * | 2008-07-08 | 2010-01-15 | Sanofi Aventis | Antagonistes specifiques du recepteur fgf-r4 |
| WO2012138975A1 (en) | 2011-04-07 | 2012-10-11 | Genentech, Inc. | Anti-fgfr4 antibodies and methods of use |
-
2015
- 2015-08-11 EP EP15748050.0A patent/EP3180356B1/en active Active
- 2015-08-11 ES ES15748050T patent/ES2764418T3/es active Active
- 2015-08-11 JP JP2017508103A patent/JP7011939B2/ja active Active
- 2015-08-11 TW TW104126103A patent/TWI710575B/zh active
- 2015-08-11 PL PL15748050T patent/PL3180356T3/pl unknown
- 2015-08-11 WO PCT/EP2015/068440 patent/WO2016023894A1/en active Application Filing
- 2015-08-11 US US15/503,095 patent/US10358498B2/en active Active
-
2020
- 2020-07-17 JP JP2020122564A patent/JP2020183418A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10358498B2 (en) | 2019-07-23 |
| WO2016023894A1 (en) | 2016-02-18 |
| ES2764418T3 (es) | 2020-06-03 |
| EP3180356A1 (en) | 2017-06-21 |
| JP2017526671A (ja) | 2017-09-14 |
| TW201619198A (zh) | 2016-06-01 |
| US20170226213A1 (en) | 2017-08-10 |
| TWI710575B (zh) | 2020-11-21 |
| JP2020183418A (ja) | 2020-11-12 |
| EP3180356B1 (en) | 2019-11-27 |
| JP7011939B2 (ja) | 2022-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252004A0 (en) | Ether-substituted antibody | |
| IL250583A0 (en) | Anti-tigit antibodies | |
| SG11201703403TA (en) | Anti-tim-3 antibodies | |
| SG11201703346PA (en) | Anti-tim-3 antibodies | |
| GB201411320D0 (en) | Antibody construct | |
| IL252422B (en) | Effector-deficient anti-cd32a antibodies | |
| IL291164A (en) | Anti-nme antibody | |
| ZA201701461B (en) | Antibody formulations | |
| PT3101132T (pt) | Anticorpo humano anti-transtirretina | |
| IL250374A0 (en) | Antibodies against ceramide | |
| PL3180356T3 (pl) | Ludzkie przeciwciało anty-fgfr4 | |
| GB201410520D0 (en) | Antibody | |
| SG11201700922YA (en) | Anti-orai1 antibody | |
| IL247988A0 (en) | Antibodies against hpa–1a | |
| GB201418776D0 (en) | Antibody | |
| GB201413745D0 (en) | Antibody | |
| GB201419092D0 (en) | Anti-TIM-3 antibodies | |
| GB201419089D0 (en) | Anti-TIM-3 antibodies | |
| GB201411319D0 (en) | Antibody | |
| GB201417614D0 (en) | Antibodies | |
| GB201407535D0 (en) | Antibody Drug - Conjugates | |
| GB201414270D0 (en) | Antibodies | |
| GB201415526D0 (en) | Antibody Formulations | |
| GB201415298D0 (en) | Antibody Formulations | |
| GB201405775D0 (en) | Antibodies |